4Bellmunt J, Albanell J, Paz AL, et al. Pretreatment prognostic factors for survival in patients with advanced urothelial tumors treated in a phase Ⅰ/Ⅱ trial with paclitaxel, cisplatin and gemcitabing [ J ]. Cancer, 2002,95 (8) : 751-757.
二级参考文献29
1Von der Mause,Hansen SW, Liepa A,et al. Health care resource use for patients with advamced blader cancer treated with gemcitabine plus cisplatin (GC)versus MVAC in a phase Ⅲ trial [J].Ann Oncol, 2000, 11 (Supp1 4):74-77.
2Khaled HM,Zaqhloul MS,Ghoneim M,et al.A randomized phase Ⅲ study of neoadjuvant chemotherapy for invasive bladder cancer with gemcitabine and cisplatin [J].Proc Ann Meet Am Soc Clin Onco l,2002,21: A2421.
3Pectasides D, Visvikis A,Aspropotamitis A,et al. Chemotherapy with cisplatin, epirubicin and docetaxel in transitional cell urothelial cancer. Phase Ⅱ trial. Eur J Cancer,2000,36:74-79.
4Dodd PM, McCaffrey JA, Hilton S, et al.Phase Ⅰ evaluation of sequential doxorubicin gemcitabine then ifosfamide paclitaxel cisplatin for patients with unresectable or metastatic transitional-cell carcinoma of the urothelial tract. J Clin Oncol, 2000, 18:
5Tanagho EA,McAninch JW. Smith' s General Urology. 15th ed. McGraw-Hill Companies, 2001. 355 -368.
6Saxman SB,Propert KJ,Einhorn LH,et al.Long-term follow-up of a Phase Ⅲ Intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Cl
7Stickle M, Meyenburg W,Wellek S,et al.Advanced bladder cancer( stage pT3b, pT4a,pN1 and pN2 ): improved survival after radical cystectomy and 3 adjuvant cycles of chemotherapy. Results of a controlled prospective study. J Urol, 1992,148:302-306.
8Natale RB, Grossman HB, Blumenstein B, et al. Randomized phase Ⅲ trial of neoadjuvant MVAC + cystectomy versus cystectomy alone in patients with locally advanced bladder cancer ( abstract 3 ). Proc Am Soc Clin Oncol,2001,20 :2.
9Sternberg CN, Parmar MK. Neoadjuvant chemotherapy is not (yet) standard treatment for muscle-invasive bladder cancer. J Clin Oncol,2001,19 (suppl) :21-26.
10Uygur MC,Yaman I,Altug U,et al. Conservative management of stage T2 or T3a bladder cancer with deep transurethral resection followed by four cycles of chemotherapy. Br J Urol,1996,78:201-204.
2Matsushima M, Kikuchi E. Clinical impact of bladder bi- opsies with TUR-BT according to cytology results in pa- tients with bladder cancer: a case control study[ J]. BMC Urol, 2010,10:12-15.
3Harada K, Itashiki Y. Effects of lentinan alone and in combination with fluoropyrimidine anticancer agent on growth of human oral squamous cell carcinoma in vitro and in vivo [ J ]. Int J Oncol, 2010,37 ( 3 ) :623-631.
4Sreenivasulu K, Vijayalakshmi M. Regulation studies of telomerase gene in cancer cells by lentinan [ J ]. Avicenna J Med Biotechnol, 2010,2(4) :181-185.
5Aranda A, Sequedo L. Dichloro-dihydro-fluorescein diac- etate (DCFH-DA) assay: a quantitative method for oxi- dative stress assessment of nanoparticle-treated cells [ J ]. Toxicol In Vitro, 2013,27(2) :954-963.
6Itani S, Kunisada T. MicroRNA-21 correlates with tumor- igenesis in malignant peripheral nerve sheath tumor (MPNST) via programmed cell death protein 4 (PDCD4) [J]. J Cancer Res Clin Oncol, 2012, 138 (9): 1501- 1509.
7Hu J, Liu X. Herceptin conjugates linked by EDC boost direct tumor cell death via programmed tumor cell necro- sis[J]. PLoS One, 2012,6(8) :270-273.
8Huddart R A, Hall E. Randomized noninferiority trial of reduced high-dose volume versus standard volume radia-tion therapy for muscle-invasive bladder cancer: results of the bc2001 trial (CRUK/01/004) [J]. Int J Radiat Oncol Biol Phys, 2013,87(2) :261-269.
9Wang J L, Bi Z. Combination therapy with lentinan im- proves outcomes in patients with esophageal carcinoma [J]. Mol Med Rep, 2012,5(3) :745-748.
10Kim S Y, Kim J H, Song J J. c-Cbl shRNA-expressing adenovirus sensitizes TRAIL-induced apoptosis in prostate cancer DU-145 through increases of DR4/5 [ J ]. Cancer Gene Ther, 2013,20(2) : 82-87.
